Therapeutic Response

EGFR Exon 20 (Insertion) status confers therapeutic sensitivity to Amivantamab in patients with Non-Small Cell Lung Cancer.

Statements

Source and description
Rybrevant (amivantamab-vmjw) [product monograph]. HC. Health Canada approved amivantamab as monotherapy for the treatment of adult patients with locally advanced or metastatic NSCLC with activating EGFR Exon 20 insertion mutations whose disease has progressed on or after platinum-based chemotherapy.
Rybrevant (amivantamab-vmjw) [package insert]. FDA. The U.S. Food and Drug Administration granted approval to amivantamab-vmjw for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy.